| Characteristic | Drug A N = 981 |
Drug B N = 1021 |
p-value2 |
|---|---|---|---|
| Age | 46 (37, 60) | 48 (39, 56) | 0.7 |
| Unknown | 7 | 4 | |
| Marker Level (ng/mL) | 0.84 (0.23, 1.60) | 0.52 (0.18, 1.21) | 0.085 |
| Unknown | 6 | 4 | |
| T Stage | 0.9 | ||
| T1 | 28 (29%) | 25 (25%) | |
| T2 | 25 (26%) | 29 (28%) | |
| T3 | 22 (22%) | 21 (21%) | |
| T4 | 23 (23%) | 27 (26%) | |
| Grade | 0.9 | ||
| I | 35 (36%) | 33 (32%) | |
| II | 32 (33%) | 36 (35%) | |
| III | 31 (32%) | 33 (32%) | |
| Tumor Response | 28 (29%) | 33 (34%) | 0.5 |
| Unknown | 3 | 4 | |
| Patient Died | 52 (53%) | 60 (59%) | 0.4 |
| Months to Death/Censor | 23.5 (17.4, 24.0) | 21.2 (14.5, 24.0) | 0.14 |
| 1 Median (Q1, Q3); n (%) | |||
| 2 Wilcoxon rank sum test; Pearson’s Chi-squared test | |||